Search alternatives:
026 decrease » _ decrease (Expand Search), nn decrease (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
026 decrease » _ decrease (Expand Search), nn decrease (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
321
Decreased capillary density and cardiac fibrosis in <i>Nkx2.5-Cre/Foxm1<sup>fl/fl</sup></i> heart.
Published 2013“…Capillary density was decreased in <i>Nkx2.5-Cre/Foxm1<sup>fl/fl</sup></i> hearts at P11 (A–B, I), while coronary vessel formation was not altered (C–D). …”
-
322
-
323
CNP decrease mitochondrial membrane potential and induce mitochondrial fragmentation in melanoma cells.
Published 2020“…<p>A, 300 μM CNP (4 h) significantly decreased mitochondrial membrane potential in A375 cells, but not in melanocytes, indicated by changes of TMRM dependent fluorescence in mitochondria. …”
-
324
-
325
SPL treatment decreases diabetes-induced decrement in protein expression of cldn-5 in glomeruli (GL) and cldn-2 and occldn in proximal tubules (PT).
Published 2017“…<p>SPL prevents diabetes-induced decrease of cldn-5 protein expression (A and B) in GL, and mRNA (F) and protein expression of cldn-2 (A and C), and protein expression of occldn (A and D) in PT (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0177362#pone.0177362.s002" target="_blank">S2 Fig</a>). …”
-
326
-
327
-
328
Sarcopenia as an Independent Risk Factor for Decreased BMD in COPD Patients: Korean National Health and Nutrition Examination Surveys IV and V (2008-2011)
Published 2016“…<div><p>Background</p><p>A decrease in bone mineral density (BMD) is a systemic consequence of chronic obstructive pulmonary disease (COPD). …”
-
329
-
330
-
331
Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.
Published 2016“…<p>Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.…”
-
332
-
333
-
334
-
335
-
336
-
337
-
338
-
339
-
340